Research programme: osteoporosis therapies - Transition Therapeutics
Alternative Names: BCA-902Latest Information Update: 24 Aug 2010
At a glance
- Originator Transition Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 15 Mar 2006 Preclinical trials in Osteoporosis in Canada (unspecified route)